vels was through prescription injections, which can cost thousands of dollars a year. This explains why some experts are calling SeroVital-hgh the scientific breakthrough of the decade. Finally, after over 30 years of research, an oral compound has been discovered that can increase bioactive, serum (blood) growth hormone levels by a mean of 682%… without the cost and inconvenience of prescription injections.
In addition to their high cost, these synthetic hGH injections are also extremely controversial, because some experts fear that introducing synthetic hGH into the body may upset the natural production of hGH.
That's what makes SeroVital-hgh so revolutionary. Rather than introducing synthetic hGH into the body like the injections, SeroVital raises the body's own, natural levels of human growth hormone by promoting pituitary health, the gland that manufactures hGH. SeroVital has not only made it more affordable for people to raise their hGH levels, but has given them a clinically proven way to raise them naturally.
So What's the Catch?
Well, there are three. First, as with hGH injections, SeroVital-hgh is not a "magic bullet" but one part of a healthy lifestyle choice including a sensible diet and exercise regimen. And, just like hGH injections, you have to remember to renew your monthly supply.
Second, you have to take SeroVital-hgh on an empty stomach. That means you either have to take it first thing in the morning and then not eat anything for two hours, or take it at night, at least two hours after your last meal... before you go to bed.
And last but not least, while SeroVital is far less expensive than prescription hGH injections, it's still not cheap… SeroVital will cost you about $100 a month. But is it worth it? To most people, reducing wrinkles, decreasing body fat, increasing lean muscle mass, strengthening bones, boosting mood, while giving you plenty of energy and improving sex drive is a no brai
Page: 1 2 3 Related medicine technology :1
|SOURCE SanMedica International|
Copyright©2012 PR Newswire.
All rights reserved
. Arena Pharmaceuticals Announces First Quarter 2012 Financial Results and Recent Developments2
. Delcath Highlights First Quarter 2012 And Recent Accomplishments3
. Soligenix Reports First Quarter 2012 Financial Results and Highlights Recent Accomplishments4
. ChromaDex® Experiencing Higher Than Expected Demand For Its Recently Launched BluScience™ Line of Dietary Supplements5
. Attorneys for Class of Female VPs and SVPs Employed by PR Giant MSLGroup Clarify Companys Inaccurate Description of Federal Courts Recent Certification Ruling6
. Ampio Advances NCE001 Cancer Drug into Preclinical Development Following Successful Recent Financing and the Granting of Patents in USA, Canada, Europe and China7
. Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population8
. Unigene Provides Update Following Recent EMA Recommendation on Calcitonin-Containing Medicines9
. Delcath Reports Second Quarter 2012 Financial Results And Highlights Recent Accomplishments10
. Arena Pharmaceuticals Announces Second Quarter 2012 Financial Results and Recent Developments11
. Soligenix Reports Second Quarter 2012 Financial Results and Highlights Recent Accomplishments